Description

Zoladex (gozerelin) capsules for subcutaneous use 3.6 mg. №1 in the syringe applicator

Ingredients

Zoladex contains the active ingredient goserelin acetate, a synthetic decapeptide analogue of naturally occurring gonadotropin-releasing hormone (GnRH).

Dosage

Zoladex 3.6 mg is administered as a single subcutaneous injection every 28 days using the provided syringe applicator.

Indications

Zoladex is indicated for the palliative treatment of advanced prostate cancer and certain gynecological conditions such as endometriosis and uterine fibroids.

Contraindications

Zoladex is contraindicated in individuals with known hypersensitivity to GnRH, pregnant or breastfeeding women, and pediatric patients.

Directions

Before administration, ensure proper reconstitution of the medication according to the instructions provided. Administer the injection subcutaneously in the abdominal area, alternating sides with each dose.

Scientific Evidence

Studies have shown that Zoladex (goserelin) effectively suppresses gonadotropin secretion, leading to a reduction in testosterone levels in prostate cancer patients. Clinical trials have demonstrated its efficacy in improving symptoms and quality of life in individuals with hormone-sensitive tumors.

Additional Information

It is important to monitor hormone levels regularly during treatment with Zoladex to ensure therapeutic effectiveness. Adverse effects may include hot flashes, fatigue, and decreased libido, which are typically transient and reversible.

Zoladex acts by initially stimulating the release of pituitary gonadotropins, which results in a transient increase in serum testosterone levels in males and estradiol levels in females. However, continuous administration leads to downregulation of GnRH receptors, ultimately suppressing gonadotropin secretion and sex hormone production.

Compared to surgical castration or anti-androgen therapy, Zoladex offers a convenient and reversible option for androgen deprivation therapy in prostate cancer. Its subcutaneous formulation provides a sustained release of the drug, ensuring therapeutic levels are maintained over the treatment period.